Aytu BioPharma, Inc. (AYTU) Earnings Call Analysis

NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic

13/25

Growth 3 Margin 2 Expansion 4 Platform 2 Financial 2

latest quarter score

Earnings Reports

13
AYTU Q2 2026: Exua Launch Engages 100+ Prescribers, Signals Early Brand Traction
June 15, 2026
14
AYTU Q3 2026: Exua Prescriptions Jump 51% as Launch Accelerates Beyond Core Markets
May 14, 2026
16
Aytu BioPharma (AYTU) Q1 2026: ADHD Portfolio Grows 10% Excluding Rebate, EXXUA Launch Advances
November 13, 2025
11
AYTU Q4 2025: $10M Exua Launch Investment Signals Strategic Pivot Beyond ADHD Volatility
September 24, 2025
21
Aytu BioPharma (AYTU) Q3 2025: 32% Revenue Growth Validates Strategic Realignment and Platform Leverage
May 14, 2025
AYTU Q1 2025: Pediatric Revenue Jumps 54% as ADHD Baseline Scripts Expand
November 13, 2024
AYTU Q4 2024: ADHD Scripts Climb 26% as Pediatric Recovery Signals Portfolio Rebound
September 26, 2024
AYTU Q3 2024: ADHD Portfolio Soars 49% as Specialty Pharma Transformation Nears Completion
May 15, 2024
AYTU Q2 2024: ADHD Portfolio Revenue Jumps 49% as Consumer Health Exit Reshapes Profitability
February 14, 2024
17
AYTU Q1 2024: ADHD Net Revenue Climbs 31% as Rx Segment Anchors Margin Expansion
November 14, 2023
AYTU Q3 2023: ADHD Scripts Surge 27% as Supply Disruptions Drive Share Gains
May 11, 2023
AYTU Q2 2023: Rx Segment Margin Flips to $3.1M Positive as ADHD Tailwinds Persist
February 21, 2023

Browse all companies